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Abstract
In this study we have investigated the role of extracellular ATP on thrombin induced-platelet aggregation (TIPA) in washed
human platelets. ATP inhibited TIPA in a dose-dependent manner and this inhibition was abolished by apyrase but not by
adenosine deaminase (ADA) and it was reversed by extracellular magnesium. Antagonists of P2Y1 and P2Y12 receptors had
no effect on this inhibition suggesting that a P2X receptor controlled ATP-mediated TIPA inhibition. ATP also blocked
inositol phosphates (IP1, IP2, IP3) generation and [Ca2+]i mobilization induced by thrombin. Thrombin reduced cAMP levels
which were restored in the presence of ATP. SQ-22536, an adenylate cyclase (AC) inhibitor, partially reduced the inhibition
exerted by ATP on TIPA. 12-lipoxygenase (12-LO) inhibitors, nordihidroguaretic acid (NDGA) and 15(S)-hydroxy-5,8,11,13-
eicosatetraenoic acid (15(S)-HETE), strongly prevented ATP-mediated TIPA inhibition. Additionally, ATP inhibited the
increase of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) induced by thrombin. Pretreatment with both SQ-
22536 and NDGA almost completely abolished ATP-mediated TIPA inhibition. Our results describe for the first time that ATP
implicates both AC and 12-LO pathways in the inhibition of human platelets aggregation in response to agonists.
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Introduction
Activation of human platelets is a key event in the processes of
hemostasis and thrombosis. Several agonists including ADP,
thrombin, and thromboxane A2 (TXA2) can activate platelets
[1]. These agonists affect platelets leading to shape change,
aggregation, or promoting that the granule release their content
[2]. Thrombin is a serine protease which is activated by extrinsic
and intrinsic coagulation cascades at the vascular injury site. It is
not only a coagulation enzyme catalysing the conversion of soluble
fibrinogen into an insoluble fibrin clot, but also an extremely
important agonist for platelet activation [3]. Thrombin primarily
mediates cellular effects through protease-activated receptors
(PARs). Three of the four PARs known (PAR1, PAR3 and
PAR4) are activated by thrombin with PAR1 and PAR4 being
present in human platelets. Both receptors are coupled to a
Gaqsubunit [4].
ADP is released during platelet activation, becoming a critical
molecule in hemostasis. ADP also cooperates with other molecules,
including thrombin, to potentiate many platelet responses [5].
Two different P2 receptors, P2Y1 and P2Y12, involved in the
ADP-induced platelet responses have been cloned. The P2Y1
receptor mediates PLC activation via a Gaq subunit and
subsequently regulates intracellular calcium ([Ca2+]i) mobilization
and platelet shape changes [5]. P2Y12 receptor, on the other hand,
is coupled to the Gai subunit, which prevents the activation of AC,
whereupon the intracellular cAMP concentration decreases.
P2Y12 receptor behaves as a negative regulator of platelet
activation [6]. The P2Y12-dependent Gai activation also potenti-
ates the release of granule contents [7] and can directly activate
the aIIbb3 integrin via phosphoinositide-3 kinase [8–11].
ADP-induced platelet aggregation requires coactivation of P2Y1
and P2Y12 receptors [12]. Thrombin and thrombin receptor-
activating peptides (TRAPs) have been shown to activate both Gaq
and Gai pathways [13] but unlike ADP, thrombin alone is unable
to activate both pathways [14]. Glycoprotein Iba and ADP act
synergistically to amplify the PAR1- but not the PAR4-coupled
responses [15]. Thrombin not only requires secreted ADP and
P2Y12 activation to stimulate Gai and activate PAR1 via Gaq but
also, at high concentrations, it can regulate PAR4 pathway [16]. It
has been described that ticagrelor and other cyclopentyltriazolo-
pyrimidines (P2Y12 antagonists) selectively block the ADP
component in the thrombin response resulting in a potent
inhibition of platelet activation whereas they are ineffective for
P2Y1 [17].
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ATP and ADP are present in platelets at approximately
equimolar concentrations [18] and extracellular ATP inhibits
ADP-induced platelet activation, since it acts as a competitive
antagonist through P2Y1 and P2Y12 receptors [19]. It has been
reported that ATP stimulates P2X1 receptor in human platelets
and increases the intracellular calcium concentration without
generating platelet aggregation [20]. Moreover, studies on
transgenic animals showed that P2X1 receptors play an important
role in platelet activation, particularly under conditions of shear
stress and thus during arterial thrombosis [21]. Besides, this
receptor could be involved in the aggregation of human platelets
induced by collagen [22].
ATP and other nucleotides such as, GTP, GDP or GDP-b-S
inhibit both thrombin- and ADP-mediated platelet activation [23].
TIPA and the inhibition of the cellular secretion mediated by ATP
is accompanied by a decrease in [Ca2+]i mobilization, this suggests
that an extracellular P2X-like site could be responsible for the
effects of these nucleotides [23]. Dragan and Ellis found that
thrombin-untreated cells, extracellular ATP, GTP and AMP
increased the 12(S)-HETE production. ATP activated 12-LO by
an unknown mechanism and increased by 3-fold the 12(S)-HETE
formation. A purinergic binding site is proposed to activate this
pathway [24].
The aim of this work was to examine the interaction between
extracellular ATP and platelets exposed to thrombin. Our results
suggest that AC and the 12-LO pathways are implicated in the
inhibition of TIPA mediated by ATP. This physiological inhibition
of human platelets in response to strong agonists is mediated by a
combined action between the P2Y12 receptor and the inhibition of
the intracellular levels of 12(S)-HETE.
Materials and Methods
Reagents
Adenosine 39, 59 biphosphate (A3P5P), fibrinogen, acid citrate
dextrose, ADA, ADP, ATP, a,b-methylene ATP, bc-methylene
ATP, benzoyl ATP, 2 methylthio ATP, apyrase, ethylenediamine-
tetraacetic acid (EDTA), ethylene glycol-bis(b-aminoethylether)-
N,N,N9,N9-tetraacetic acid (EGTA), N-[2-hydroxyethyl] pipera-
zine-N9-[2-ethanesulfonic acid] (HEPES), 15(S)-HETE, 3- isobu-
tyl-1-methylxanthine (IBMX), milrinone, dipyridamole, NDGA,
protein kinase, 39, 59-cyclic AMP dependent (PKA), polyethyle-
nimine, sodium nitroprusside (SNP) and thrombin were obtained
from Sigma-Aldrich Chemical (St. Louis MO, USA). Fura-2 AM
was from Molecular Probes (Eugene OR, USA). Myo-[2-3H]ino-
sitol was from GE Healthcare (Barcelona, Spain). Dowex AG1-X8
column was from Bio-Rad Laboratories (Hercules PA, USA).
Trichloroacetic acid (TCA) was purchased from Panreac (Barce-
lona, Spain). 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ)
was from Alexis Biochemicals (San Diego CA, USA), 9-(tetra-
hydro-2-furyl)adenine (SQ-22536) was obtained from (Calbio-
chem-Novabiochem Corporation (San Diego CA, USA). 12(S)-
HETE levels were measured using an EIA kit according to the
manufacturer’s instructions (Assay Designs, Ann Arbor MI, USA).
Platelet Aggregation Measurement
Platelets were acquired from the Blood Bank at the Galdakao
Hospital in Spain. Platelet aggregation was carried out as
described previously [25,26]. Briefly, washed human platelets
were resuspended in HEPES buffer (10 mM HEPES pH 7.4,
145 mM NaCl, 5 mM KCl, 10 mM Glucose); apyrase free at
2.56108 cells/ml, aliquoted in 500 ml and placed in siliconized
glass cuvettes and prewarmed at 37uC without stirring. The
samples were then placed into a thermostatted aggregometer at
37uC (Menarini model Aggrecorder II PA-3220) and stirred before
treatment. Aggregation was measured as the percentage of the
maximum change in light transmission against a buffer blank for
10 min. All assays were performed in the presence of 1 mM
CaCl2.
[Ca2+]i Mobilization
[Ca2+]i levels were monitored and calculated as described
[25,27]. Briefly, washed human platelets at 2.56108/ml in a
nominally Ca2+-free standard medium (no added chelator or
CaCl2; pH 7.4) were loaded with 1 mM Fura-2 AM and 0.018 U/
ml apyrase grade V at 37uC for 45 min. Subsequently, acid citrate
dextrose was added (2% vol/vol; pH 6.5), and cells were washed
by centrifugation (3506g, 20 min, 20uC). Finally, cells were
resuspended in fresh standard medium; apyrase-free at 26108
cells/ml. Cell aliquots (0.5 ml) were transferred to a cuvette and
prewarmed at 37uC for 5 min.
Fluorescence was measured with a spectrofluorimeter (SLM
Aminco Bowman Series2, SLM) equipped with a thermostated cell
holder and a magnetic stirrer. Fura-2 fluorescence was monitored
continuously using monochromator settings of 340 and 380 nm
(excitation) and 505 nm (emission). These experiments were
performed either in the presence of 1 mM CaCl2 or without
external Ca2+ but with 2 mM EGTA-K2-H2.
[3H]inositol Phosphates Generation
Measurement of [3H]inositol phosphates was carried out as
described [25]. Briefly, washed human platelets were incubated
with myo-[2-3H]inositol at 37uC for 3 hours. Subsequently, cells
were washed and resuspended in HEPES buffer (pH 7.4) at 6–
86108 cells/ml and then allowed to rest for $25 min before
experimentation. Platelet suspensions (0.5 ml) were prewarmed at
37uC for 5 min followed by placing them into the aggregometer
(37uC) and stirred. After stimulation, reaction was stopped by
adding 0.5 ml ice-cold 10% (vol/vol) perchloric acid. Samples
were centrifuged at 1,0006g for 5 min at 4uC, and the
supernatants were neutralized with 1.5 M KOH/75 mM HEPES
and recentrifuged at 1,5006g for 5 min at 4uC. The supernatant
was diluted with 10 mM HEPES (pH 7.4)/2 mM EDTA. The
[3H]inositol phosphates were separated by anion-exchange
chromatography on a Dowex AG1-X8 column as described
[25,26]. The radioactivity was measured in a liquid scintillation
counter Tri-Carb (model 2700 TR Series; Packard Instrument
Company, Meriden, CT).
cAMP Accumulation
Washed human platelets at 46109 cells/ml were aliquoted in
350 ml and placed into the aggregometer in a siliconized glass
cuvettes warmed at 37uC and stirred before treatment. In order to
prevent the rapid degradation of cAMP by the well known
phosphodiesterases type II, III and V present in platelets [28], cells
were preincubated with a mixture of specific inhibitors (1 mM
IBMX, 10 mM milrinone and 50 mM dipyridamole) for 5 min.
Then, cells were incubated in the presence of agonists at different
times. After stimulation, the reaction was stopped by the addition
of ice-cold 10% TCA. Samples were kept on ice for 30 min and
centrifuged at 21,0006g for 5 min at 4uC. The supernatants were
collected and washed 4 times with 4 volumes of water-saturated
diethyl ether. The aqueous phase was dried up in a SpeedVac
model Savant AS290 concentrator and resuspended in 180 ml
water. cAMP concentrations were determined as described [29].
cAMP levels were also measured in the absence of phophodiester-
ase inhibitors. Finally, D[cAMP] (pmol/109 platelets) represents
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increases of cAMP levels relative to the basal concentration
measured on each experimental point.
Measurement of the Levels of 12(S)-HETE by
Immunoassay
Washed human platelets at 16109 cells/ml were aliquoted in
500 ml and placed before treatment into the aggregometer in a
siliconized glass cuvettes warmed at 37uC and stirred. Cells were
preincubated with 25 mM NDGA or vehicle for 5 min and
subsequently were treated with 500 mM ATP or vehicle for 2 min
at 37uC. Finally, cells were stimulated with 0.025 U/ml thrombin
for 10 minutes at 37uC in the presence of 1 mM CaCl2. After the
stimulation, 2 volumes of methanol were added and the samples
were stored at 220uC. To measure 12(S)-HETE, 50 ml superna-
tants of stimulated platelets were evaporated under a stream of N2,
and the residue was resuspended with 250 ml of ice-cold phosphate
buffer saline. 12(S)-HETE levels were measured using an EIA kit
according to the manufacturer’s instructions (Assay Designs, Ann
Arbor, MI).
Statistical Analysis
Results are expressed as means 6 s.e.m. of the number of
experiments indicated. Statistical significance between various
conditions was assessed with Student’s t test.
Results
ATP Inhibits Platelet Aggregation Mediated by Thrombin
Washed human platelets were incubated with different concen-
trations of ATP (from 1 mM to 1 mM) for 2 min and were then
stimulated with 0.025 U/ml thrombin for 2, 4, 6 8 and 10 min. As
shown in Figure 1A, ATP concentrations, higher than 10 mM
inhibited both phases of platelet aggregation in response to
thrombin, the primary response-rate of aggregation, and the final
response-maximal aggregation. The presence of 1 mM Mg2+
partially reversed the inhibition of TIPA mediated by ATP
(Table 1). At higher concentrations Mg2+ significantly inhibited by
itself the extent of TIPA (data not shown). 1 mM Mg2+ increased
the IC50 for ATP from ,250 mM up to ,1 mM. These results
suggested that ATP-mediated inhibition of platelet aggregation
was ATP42 dependent. Additionally increasing the concentration
of thrombin also shifted to the right the IC50 for ATP (1.2 mM
and 4.6 mM at 0.05 U/ml and 0.5 U/ml thrombin, respectively)
(Figure 1B).
Next, we investigated whether ATP-mediated inhibition of
TIPA was time-dependent. Washed human platelets were
incubated with different concentrations of ATP (100, 250,
500 mM) for 0, 2, 5, 10, 20, 30, 60 and 90 minutes and were
then stimulated with 0.025 U/ml thrombin. At time 0 platelets
were exposed simultaneously to both ATP and thrombin. In all
time points maximal aggregation was measured 10 minutes after
addition of thrombin including time 0. As shown in Figure 2 the
inhibition of TIPA mediated by nucleotide was very fast at all ATP
concentrations (1565%, 4165%, 73613% at 100, 250 and
500 mM ATP, respectively). This inhibitory effect slightly
increased with incubation time (maximum at 2 min for 100 mM
ATP and 5 min for 250 and 500 mM ATP) followed by a strong
decrease in the inhibition carried out by ATP mainly at 100 and
250 mM, respectively (Figure 2).
Effects of Selective Antagonists of ADP Receptors, P2Y1
and P2Y12, on the TIPA Inhibition Induced by ATP
It is widely accepted that extracellular ATP is a competitive
antagonist of ADP-induced platelet activation [19]. To examine
the potential implication of ADP receptors in the ATP-mediated
inhibition of TIPA, we studied the effect of A3P5P, a selective
antagonist for P2Y1 receptor and 2-propylthio-b,c-difluoromethy-
lene-D-ATP (AR-C67085), a structural analogue of ATP and a
selective antagonist for P2Y12 receptor. Washed human platelets
were preincubated or not with these compounds followed by
incubation in the presence or absence of ATP and finally
stimulated with 10 mM ADP. As shown in Figure 3 (A,B) ADP-
induced platelet aggregation and this aggregation was strongly
blocked by both P2Y selective antagonists (64% for 200 mM
A3P5P; n = 3, P,0.01 and 68% for 100 nM AR-C67085, n = 5,
P,0.01) and by 50 mM ATP (79%, n = 5, P,0.001). The effect of
ATP on this response was marginally increased by co-incubation
with either A3P5P or AR-C67085 (n = 5, P.0.05). Similar
approach was developed to study the effects of these antagonists
on the thrombin response. In this case, neither A3P5P nor AR-
C67085 significantly modified the platelet aggregation induced by
thrombin (Figure 4 A,B). However, AR-C67085 slightly increased
(23610%) the inhibitory effect produced by 250 mM ATP
(Figure 4B). Next, the combination of both compounds had a
small inhibitory effect on the rate and extent of aggregation
(661%) on thrombin-stimulated platelets (Figure 4C). While the
pretreatment of platelets with both compounds slightly increased
(1465%) the inhibitory effect induced by 250 mM ATP
(Figure 4C).
Effect of ADA and Apyrase on the TIPA Inhibition
Induced by ATP
ATP effect on TIPA could be explained by the fast ATP
hydrolysis to generate first AMP and subsequently adenosine, a
well-known TIPA inhibitor. To test this possibility we examined
the effect of ADA on our experimental system. As shown in
Figure 5A, 1 U/ml ADA totally prevented TIPA inhibition
induced by 10 mM adenosine (Fig. 5A, bars 2 and 6) in cells
exposed to 0.025 U/ml thrombin. However, ADA was unable to
modify the inhibitory effect of ATP on TIPA, both at 500 as
250 mM ATP (Fig. 5A, bars 3 and 7 and 4 and 8).
Further, to confirm that ATP itself was responsible for TIPA
inhibition, we examined the effect of apyrase on platelet
aggregation. Apyrase alone had no effect on TIPA (Figure 5B).
Moreover, apyrase in the presence of ATP abolished the inhibitory
effect induced by this nucleotide on platelet aggregation. The
inhibition was reversed by 70% compared to platelets treated with
thrombin and ATP in the absence of apyrase (Figure 5B). These
results suggest that the presence of ATP in the incubation medium
is required to observe the inhibitory effect on thrombin induced
platelet aggregation.
ATP Inhibits Second Messengers Generation Controlled
by Thrombin
Activation of platelets by thrombin involves phospholipase C
(PLC) activation and is accompanied by an increase in [Ca2+]i
mobilization and cation entry from the extracellular environment
[5]. In order to decipher the mechanism by which ATP inhibited
platelet aggregation, we studied the effect of ATP on thrombin-
induced [Ca2+]i release in platelets. As shown in Figure 6A (upper
panel), thrombin-induced robust intracellular calcium mobiliza-
tion, from a baseline of 41 nM raise to 128 nM giving a maximum
increase of 8765 nM, however, this response was progressively
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and significantly inhibited by ATP in a dose dependent-manner.
Maximal inhibition occurred in the presence of 3 mM ATP. Next,
we studied the contribution of calcium from intracellular stores.
To this end, the extracellular calcium was chelated with 2 mM
EGTA. In these conditions thrombin induced a significant
increase in intracellular calcium concentration (3863 nM). This
response was also blocked by ATP in a dose dependent-manner
(Figure 6B, lower panel). Furthermore, ATP did not affect the
basal [Ca2+]i neither in the presence nor in the absence of
extracellular calcium. These results suggested that ATP interfered
negatively with early signals controlled by thrombin in the platelet
aggregation process.
A key element in early signalling is the PLC, which mediates
inositol phosphate break-down to generate IP3, DAG and [Ca2+]i.
In order to investigate whether ATP blocked PLC activation
mediated by thrombin, we examined inositol phosphate genera-
tion in platelets. As shown in Figure 6B, ATP inhibited
significantly in a dose dependent-manner inositol monophosphate
(IP1), bisphosphate (IP2) and trisphosphate (IP3) generation
induced by all thrombin concentrations tested (from 0.025 U/ml
to 0.5 U/ml). Moreover, maximal concentration of ATP (3 mM)
inhibited also basal levels of IP1, IP2, IP3 by 39, 17 and 11%,
respectively. Taken together these results indicate that ATP blocks
platelet aggregation induced by thrombin and this process should
require PLC activation to induce inositol phosphate generation
and calcium mobilization.
Effect of ATP on cAMP Generation in Human Platelets
In order to investigate the involvement of cyclic nucleotides and
cyclic nucleotide-dependent protein kinases in the ATP-mediated
inhibition of platelet responses, first we tested the guanylate cyclase
inhibitor, ODQ which abolish the inhibitory effect of 10 mM SNP,
(a nitric oxide donor that activates guanylate cyclase) on TIPA
[26,30]. This compound did not prevent the platelet aggregation
inhibition induced by 500 mM ATP suggesting that guanylate
cyclase/cGMP pathway was not involved in this process (data not
shown). Moreover, we tested an adenylate cyclase (AC) inhibitor,
SQ-22536 even when this AC inhibitor did not modify the basal
TIPA, this AC inhibitor was able to partially block the inhibition
induced by ATP over TIPA (Figure 7D). Next, we studied the
effect of ATP on the cAMP accumulation in human platelets.
First, to avoid cAMP degradation, we performed these experi-
ments in the presence of different phosphodiesterase inhibitors, as
described in Materials and Methods. As shown in Figure 7A, ATP
and its non-metabolizable analog, a,b-methylene ATP, increased
cAMP levels in a time-dependent manner reaching the maximun
cAMP concentration after 5 min (961, 1161 and 761 pmol/109
cells for 500 mM ATP, 1 mM ATP and 500 mM a,b-methylene
ATP respectively, n = 5, P,0.01). Longer incubations (up to
30 min) significantly reduced the increases in cAMP levels induced
by 500 mM ATP (461 pmol/109 cells, n = 5, P,0.05) but did not
affect the response to 1 mM ATP or a,b-methylene ATP (n = 5,
Figure 1. Inhibition of thrombin-induced platelet aggregation by ATP. Washed human platelets were preincubated with different
concentrations of ATP or vehicle for 2 min. Then, cells were stimulated with (A) 0.025 U/ml thrombin (Y, time= 0 and (B) with different thrombin
concentrations: 0.025 U/ml (m), 0.05 U/ml (¤), 0.1 U/ml (&) or 0.5 U/ml (.). The aggregation was measured for 10 min. (A) Values represent the
average curves (%, means6 s.e.m) of 6 experiments with different platelet preparations. (B) Values represent the extent of aggregation at 10 minutes
(%, means 6 s.e.m) of 6 experiments with different platelet preparations. Error bars are omitted when smaller than symbols.
doi:10.1371/journal.pone.0067117.g001
Table 1. Effect of Mg2+ on ATP-mediated inhibition of TIPA.
Maximal Aggregation (%)
[ATP] (mM) 2 Mg2+ + Mg2+
0 9162 9062
0.001 8862 8565
0.01 8365 8365
0.1 6369 7765
0.5 1468 6666
1 060 4666
2 060 060
Washed human platelets were preincubated with different concentrations of
ATP for 2 min in the absence (2Mg2+) or in the presence (+Mg2+) of 1 mM
MgCl2. Then, cells were stimulated with 0.025 U/ml thrombin. The aggregation
was measured for 10 min. Values represent the average of maximal
aggregation (% means6s.e.m) of 7 experiments with different platelet
preparations.
doi:10.1371/journal.pone.0067117.t001
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P.0.05). Then, we examined whether cAMP accumulation could
be detected in the absence of phosphodiesterase inhibitors. To do
this, washed human platelets were treated with different concen-
trations of ATP for 5 minutes and cAMP levels were measured as
described in Materials and Methods. As shown in the inset of
Figure 7 A, ATP induced an increase of intracellular cAMP levels
in a dose-dependent manner. This increment were about 2 and 5
for 500 mM and 1 mM ATP respectively, whereas for the same
concentrations of ATP in platelets which were pretreated with
phosphodiesterase inhibitors the increments were about 9.5 and 11
(Figure 7A and inset). Nevertheless in the absence of inhibitors, the
increment of cAMP was undetectable for 10 mM ATP and weakly
detectable for 100 mM ATP, while at the same concentrations of
ATP in the presence of phosphodiesterase inhibitors the incre-
ments were about 4.8 and 5.4 for 10 and 100 mM ATP
respectively (Figure 7A inset compared to Figure 7C, first and
second solid bars). Since, cAMP signal was amplified by using the
cocktail of phophodiesterase inhibitors, we decided to perform the
other experiments related with the intracellular cAMP detection in
the presence of phosphodiesterase inhibitors.
Next, we studied the effect of ATP on cAMP levels in thrombin-
stimulated human platelets. Consistent with the results obtained by
Kim et al. [31], we also found that 0.025 U/mL thrombin
reduced basal cAMP levels in a time-dependent manner
(2661 pmol/109 cells with respect to basal levels after 5 min,
n = 5, P,0.01) (Figure 7B). However, when platelets were
preincubated with 1 mM ATP for 2 minutes, followed by
stimulation with thrombin (0, 2, 5 and 10 minutes), ATP not
only blocked the effects of thrombin on the decreased of
intracellular cAMP, but also ATP did the reverse effect, increasing
cAMP to a value of 9 pmol/109 cells (Figure 7B). Nevertheless,
thrombin did not modify the cAMP accumulation in response to
different concentrations of ATP (Figure 7C). These results
suggested that ATP inhibition over agonist-induced platelet
aggregation required AC/cAMP pathway.
In a next set of experiments cAMP levels were measured in
thrombin-stimulated platelets preincubated with AR-C67085 and
treated or not with ATP. As shown in Figure 8, AR-C67085
increased cAMP levels in a dose-dependent manner, compared to
control (platelet incubated with thrombin alone). Similar cAMP
accumulation was observed in platelets incubated only in the
presence of AR-C67085 (data not shown). When platelets were
incubated first with different concentrations of AR-C67085
followed by 500 mM ATP, ATP also increased the cAMP
intracellular levels in an AR-C67085 concentration independent
manner. No potentiation or additive effect was observed by the
combination of both P2Y12 receptor antagonists. Taken together
these results suggested that ATP signalled through P2Y12 receptor
in platelets to generate cAMP.
NDGA Reverses the Platelet Aggregation Inhibition
Mediated by ATP
12-LO and its metabolites are involved in the control of platelet
response [32]. Based on this, we investigated the potential
implication of this enzyme on the TIPA inhibition exerted by
ATP. We preincubated platelets with different concentrations of
NDGA (a potent lipoxygenases non-specific inhibitor) for 5
minutes, followed by 250 or 500 mM ATP and finally platelets
were stimulated with thrombin. As shown in Figure 9A, the
Figure 2. TIPA inhibition mediated by nucleotide is ATP time- and dose- dependent. Washed human platelets were incubated for various
times (from 0 min to 90 min as indicated) with different ATP concentrations or vehicle. Then, cells were stimulated with 0.025 U/ml thrombin for 10
minutes. At 0 minutes ATP and thrombin were added simultaneously and maximal aggregation was measured after 10 min. Values represent the
average of maximal aggregation (%, means 6 s.e.m) of 3 experiments with different platelet preparations.
doi:10.1371/journal.pone.0067117.g002
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inhibition of platelet aggregation mediated by 250 and 500 mM
ATP (4563% and 7465% respectively) was significantly reversed
by NDGA at concentrations between 25 and 75 mM. Thereby in
the presence of 25, 50 or 75 mM NDGA, the maximal inhibition
was 2367% (*P,0.05), 1366% (**P,0.01) and 0610%
(**P,0.01), respectively. Resulting in a reversion of the inhibition
induced by 250 mM ATP (50610% (P,0.05), 73613% (P,0.01)
and 10064% (P,0.01) at 25, 50 and 75 mM NDGA respectively,
n = 429; Figure 9A). At 500 mM ATP and in the presence 25, 50
or 75 mM NDGA the reversion of inhibition was 60612%
(***P,0.001), 7868% (**P,0.01) and 69612% (*P,0.05)
respectively (Figure 9A). We observed that 50 and 75 mM but
not 25 mM NDGA inhibited the maximal platelet aggregation
1061% and 2663%, respectively (Figure 9A, solid squares),
therefore we decided to use 25 mM NDGA in the next
experiments.
To further confirm that concentrations of NDGA lower than
50 mM could significantly reverse the inhibition of TIPA mediated
by ATP, we examined the effect of 25 mM NDGA on this process.
As expected, 25 mM NDGA alone had no effect on TIPA
Figure 3. Effect of A3P5P and AR-C67085 on ADP-induced platelet aggregation. Washed human platelets were preincubated with (A)
200 mM A3P5P or vehicle for 10 min and (B) with 100 nM AR-C67085 or vehicle for 10 min. Then, cells were incubated with 50 mM ATP or vehicle for
2 min. Finally, cells were stimulated with 10 mM ADP (Y, time= 0) in the presence of 0.3 mg/ml fibrinogen (added 1 minute before ADP). The assay
was performed in the presence of 1 mM CaCl2. The aggregation was measured for 10 min and values represent the average curves of aggregation
(%, means 6 s.e.m) of 5 experiments with different platelet preparations.
doi:10.1371/journal.pone.0067117.g003
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(Figure 9B). Moreover, this concentration of inhibitor in the
presence of ATP was able to reverse the aggregation blockage by
45% compared to platelets treated with thrombin and ATP in the
absence of 25 mM NDGA (Figure 9B).
Next, we also examined the activity of 12-LO by measuring
12(S)-HETE generation. As shown in Figure 9C, thrombin
stimulated 12(S)-HETE accumulation by more than 14-fold
(second bar, hatched,) over control (first bar, empty bar). The
generation of 12(S)-HETE due to LO activity was blocked when
platelets were preincubated with 25 mM NDGA followed by
thrombin stimulation (Figure 9C, fourth bar, hatched), however, in
the same experimental conditions, NDGA did not inhibit platelet
aggregation induced by thrombin (Figure 9B). Regarding the
ATP, this nucleotide (500 mM) inhibited the thrombin-response
over platelet aggregation (Figure 9B) and also reversed totally
12(S)-HETE concentration to basal level (Figure 9C, third and
sixth bars, solids). Nevertheless, we found that in non-thrombin
stimulated cells, extracellular ATP does not affect basal levels of 12
(S)-HETE (Figure 9C, first bar, empty). Taken together these
results suggested that the signaling pathway related to LO and
gluthatione peroxidase is crucial on the inhibition of the
aggregation performed by ATP, since when it is blocked, the
nucleotide effect is reversed around 60% (Figure 9B).
However, it was not clear the role of 12(S)-HETE in this
process. To clarify this point, we examined directly the effects of
two arachidonic acid metabolites, 12(S)-HETE and 12(S)-HpETE
on aggregation induced by thrombin in our experimental
conditions. Platelets were incubated with different concentrations
of those metabolites for 2 min followed by 0.025 U/ml Thrombin
in the presence of 1 mM CaCl2, maximal aggregation was
determined at 10 minutes. As shown in the inset of the Figure 9C,
results indicated that neither 12(S)HpTE nor 12(S)-HETE were
able to modify the platelet aggregation led by thrombin.
To investigate whether the effect of NDGA on ATP-mediated
inhibition of TIPA was due to some interference in the
cycloxygenase route, we tested the effect of 15(S)-HETE, a specific
inhibitor of platelet 12-LO without any effect on cycloxygenase
[33]. 15(S)-HETE did not significantly affect platelet aggregation
in response to thrombin. Nevertheless, as well as NDGA, 5 mM
15(S)-HETE reversed the ATP-mediated inhibition of TIPA
(Figure 10A, 67610% (n = 4, P,0.01).
Finally, we studied the effect of both NDGA and SQ-22536 on
ATP-mediated inhibition of platelet aggregation. Results show
Figure 4. Effect of ADP receptor antagonists on the TIPA inhibition mediated by ATP. Washed human platelets were preincubated with
(A) 200 mM A3P5P or vehicle for 10 min, (B) 100 nM AR-C67085 or vehicle for 10 min and (C) 200 mM A3P5P +100 nM AR-C67085 or vehicle for 10 min.
Then, cells were incubated in the presence of ATP or vehicle for 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin (Y, time= 0 ). The
aggregation was measured for 10 minutes and values represent the average curves of aggregation (%, means 6 s.e.m) of 5 experiments with
different platelet preparations.
doi:10.1371/journal.pone.0067117.g004
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that combined incubation with NDGA and SQ-22536 did not
affect TIPA significantly (n = 6, P.0.05; Figure 9D). However,
ATP-mediated inhibition of TIPA was almost totally blocked.
Inhibition of maximal aggregation by ATP alone was 7665%,
while it reached only 1266% when both NDGA and SQ-22536
were present (Figure 10B).
Taken together these results suggested that ATP controlled
intracellular antiaggregation signals through 12(S)-LO pathway.
Figure 5. Effect of ADA and apyrase on the ATP-mediated inhibition of TIPA. (A) Washed human platelets were pretreated with 1 U/ml
adenosine deaminase (+ ADA) or vehicle (- ADA) for 2 min. Cells were then incubated with 10 mM adenosine, 250 mM ATP, 500 mM ATP or vehicle
(Control) for 2 min, and subsequently, stimulated with 0.025 U/ml thrombin (Y, time= 0). Histogram represent the values of maximal aggregation (%,
means 6 s.e.m) of 3 experiments with different platelet preparations. *P,0.05, **P,0.01. (B) Washed human platelets were pretreated with 500 mM
ATP or vehicle for 2 min, and subsequently with 0.5 U/ml apyrase or vehicle for 1 min. Finally, platelets were stimulated with 0.025 U/ml thrombin.
The aggregation was measured for 10 min and values represent the average curves of aggregation (%, means 6 s.e.m) of 3 experiments with
different platelet preparations.
doi:10.1371/journal.pone.0067117.g005
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Discussion
In the present work we have shown that ATP were able to
inhibit the aggregation of platelets in response to thrombin. The
concentration of ATP in platelet granules is very high (between
100 and 400 mM) [34,35] and the degranulation of platelets
transiently increases the concentration of ATP in a range between
50 and 100 mM [36,37]. Thus, the local concentration of ATP is
probably much higher than the plasma concentration following
platelet activation by thrombin [38]. Considering that the
concentrations of ATP used in this work were very high, it could
be argued that they would not correspond to physiological
conditions, however, this assumption could be misleading, since
it is recognized that the active form of ATP that regulates some
P2X receptors activity is the free tetraionic form (ATP42) [39,40].
The complexation of ATP by divalent and monovalent cations
reduces significantly the concentration of the active form of ATP.
The major decrease of ATP42 concentration occurs in the
presence of Mg2+ [40]. In a Mg2+ free medium containing 1 mM
ATP and in the presence of Ca2+, Na+ and K+, the concentrations
of the active form of ATP are between 30 and 60 mM [40,41].
These effective concentrations correlate within the range of
concentrations of ATP found after platelet degranulations [36,37].
Aggregation studies showed that the inhibition mediated by
ATP was very rapid and dependent of this nucleotide, since pre-
incubations with different concentrations of ADA (which com-
pletly block adenosine effects on platelet aggregation) had no effect
on ATP-mediated inhibition of TIPA [42]. Platelets incubated
with ATP beyond 15 minutes produced a decrease in the
Figure 6. Effect of ATP on the thrombin-induced [Ca2+]i mobilization and inositol phosphate generation. (A) Fura 2-loaded human
platelets were incubated for 2 min with different concentrations of ATP (from 0 to 3 mM) in the presence (upper panel) or in the absence of 1 mM
CaCl2 (lower panel). Then, cells were stimulated with 0.025 U/ml thrombin and the increase in [Ca
2+]i was measured for 90 s. The results are expressed
as the variation of the [Ca2+]i (D [Ca
2+]i) measured before the addition of thrombin (basal level) and after the addition of thrombin (the maximum
increase in [Ca2+]i). Histograms represent the means6 s.e.m of 5 experiments with different platelet preparations. In unstimulated cells the basal level
in the presence of external calcium was 4161 nM and in the presence of EGTA was 3061 nM. In both cases, ATP did not affect the basal levels.
**P,0.01, ***P,0.001. (B) [3H]Inositol-labeled platelets were incubated for 2 min with 0.5 (m), 1 (N), 3 mM (.) ATP or vehicle (&). Then, cells were
stimulated with different concentrations of thrombin (0, 0.025, 0.05, 0.1 and 0.5 U/ml) in the presence of 1 mM CaCl2. The reaction was stopped
10 min after the stimulation. Data are the means 6 s.d. of one experiment performed in triplicate and representative of 2 other experiments. Inositol
monophosphate (upper panel, IP1), inositol bisphosphate (middle panel, IP2), and inositol trisphosphate (lower panel, IP3) were separated by anion-
exchange chromatography on a Dowex AG1-X8 column. Error bars are omitted when they are smaller than symbol. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0067117.g006
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inhibition of the platelet aggregation. This reduction could be due
either to a slow desensitization of the putative purinergic receptor
involved in the response or to the action of ectonucleotidases or
more likely of ectoapyrases bound to the platelet membrane in
humans and rodents [42,43]. In fact, the presence of apyrase in
our experimental conditions corroborated that the observed
inhibition on platelet aggregation was ATP dependent.
Besides aggregation, we found that ATP also inhibited the
increase of the [Ca2+]i induced by thrombin being this inhibition
independent of the extracellular calcium, moreover, ATP also
inhibited phosphatidyl inositol break-down at all concentrations of
thrombin tested. These results suggest that PLC activity is affected
by ATP. In agreement with that, Soslau et al. reported that
extracellular ATP inhibited the calcium mobilization from
intracellular pools by various agonists like collagen, thrombin or
an analogue to thromboxane A2 [44,45]. Similarly, we have
described a mechanism independent of calcium influx, in which
calcium increases induced by carbachol can be blunted by the
activation of a P2X receptor with low affinity for ATP [46].
However, this inhibitory effect of ATP on intracellular calcium
increases is controversial, it has also been reported that the ATP
released from activated platelets induces intracellular calcium
increases through P2X1 receptors [47–49]. These contrary results
are probably due to differences in the experimental procedures. In
order to prevent P2X1-receptor desensitization, platelet prepara-
tions were treated with apyrase [47–49]. While in our conditions
Figure 7. Effect of ATP on the cAMP levels in human platelets. (A) Washed human platelets were preincubated with a mixture of
phosphodiesterase inhibitors for 5 min at 37uC, as indicated in Materials and Methods. Then, cells were incubated with 500 mM (N) or 1 mM (.) ATP,
(&) 500 mM a,b-methylene ATP or vehicle for 2, 5, 10, 20 and 30 min. Inset, Washed human platelets were incubated with different concentrations of
ATP for 5 min at 37uC in the absence of phosphodiesterase inhibitors. The reactions were stopped by addition of ice-cold TCA (10% final
concentration). The cAMP levels were determined as described in Materials and Methods. Data represent the means 6 s.e.m of 5 (A) and 3 (inset)
experiments with different platelets preparations, performed in duplicate and assayed in triplicate. (B) Washed human platelets were preincubated
with a mixture of phosphodiesterase inhibitors for 5 min at 37uC, as indicated in Materials and Methods. Then, cells were incubated with or without
1 mM ATP for 5 min at 37uC. Finally, cells were estimulated with 0.025 U/ml for 0, 2, 5 and 10 min in the presence of 1 mM CaCl2. The reaction was
stopped by addition of ice-cold TCA (10% final concentration). The cAMP levels were determined as described in Materials and Methods. Data are the
means 6 s.e.m of 5 experiments with different platelets preparations, performed in duplicate and assayed in triplicate. (C) Washed human platelets
were also preincubated with a mixture of phosphodiesterase inhibitors for 5 min followed by incubation in the presence of various concentrations of
ATP or vehicle for 5 min and finally stimulated with 0.025 U/ml thrombin or vehicle for 5 min in the presence of 1 mM CaCl2. The reaction was
stopped by addition of ice-cold TCA (10% final concentration). The cAMP levels were determined as described in Materials and Methods. Data are the
means 6 s.e.m of 5 experiments with different platelets preparations, performed in duplicate and assayed in triplicate. *P,0.05, **P,0.01,
***P,0.001. (D) Washed human platelets were preincubated with 200 mM SQ-22536 or vehicle for 2 min. Then, cells were incubated with 500 mM
ATP or vehicle for additionally 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin (Y, time= 0). The aggregation was measured for 10 min
and values represent the average curves of aggregation (%, mean6s.e.m) of 4 experiments with different platelet preparations.
doi:10.1371/journal.pone.0067117.g007
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apyrase was not used, this absence pointed out that P2X1 receptor
would not be involved in this early signalling due to this receptor
desensitizes in milliseconds without the presence of apyrase
[20,48,50–52].
Many compounds exert their inhibition on TIPA through an
increase in basal levels of cyclic nucleotides such as prostaglandins
and NO donors [26,53,54]. ATP and a,b-methylene ATP
produced a dose- and time-dependent increase in cAMP
concentration. The increase in cAMP was rapid and transient,
especially in the presence of ATP. This kinetic was probably due to
the decrease of ATP concentration by ATP-specific ecto-apyrases.
ODQ, a guanylate-cyclase inhibitor, did not alter the effect of
ATP, suggesting that the increase in cAMP was not the result of
the inhibition of the cyclic nucleotide phosphodiesterase type 3 by
cGMP [53]. SQ-22536, an AC inhibitor, partially blocked the
inhibition exerted by ATP on TIPA. According with that, Soslau
et al. using 29,59-dideoxyadenosine as an AC inhibitor, reported
that this compound partially reversed ATP-mediated inhibition of
collagen-induced aggregation [55].
The levels of cAMP in platelets play a key role in the control of
the activation/aggregation by thrombin. Eigenthaler et al. esti-
mated that intracellular cAMP concentration in unstimulated
washed platelets was 4.4 mM, similar to the concentration of
cAMP binding sites of PKA [56]. Slight increases or decreases in
these cAMP levels are sufficient to regulate in a positive or
negative manner the activity of PKA and consequently the
platelets are relaxed or activated [53,57].
Thrombin reduces cAMP concentrations below the basal levels
through the ADP secreted from dense granules in thrombin
activated platelets [16,31,45]. ATP had the opposite effect,
increasing cAMP levels independently of the presence of
thrombin. When platelets were incubated at the same time with
ATP and AR-C67085, a specific antagonist of P2Y12 receptors,
AR-C67085 also increased in a dose-dependent manner the
cAMP levels with a maximum increase at 10 mM. No potentiation
or additive effect was observed when AR-C67085 was added to a
maximal concentration of ATP, suggesting that ATP was acting
on P2Y12 receptors with low affinity [58].
It has been reported that ADP contributes to platelet
aggregation in response to low concentrations of thrombin [58].
However, we observed that apyrase did not significantly modify
maximum aggregation induced by 0.025 U/ml thrombin. This is
consistent with the results obtained by Ishii-Watabe et al. who
reported that apyrase did not affect aggregation induced by
0.1 U/ml thrombin but fully inhibited the plasmin-induced
aggregation [59]. The pharmacological inhibition of P2Y1
receptors with the antagonist A3P5P or N6-methyl-29-deoxyade-
nosine-39,59-bisphosphate (MRS2179) had no effect on TIPA and
it had no additional effects in combination with AR-C69931, an
antagonist of P2Y12 [16]. These results confirmed those obtained
from P2Y1 receptor-null mice, in which the absence of expression
of these receptors did not affect TIPA [60]. The blockade of P2Y12
receptors with AR-C67085 did not inhibit thrombin-induced
irreversible platelet aggregation; it slightly inhibited both phases of
platelet aggregation, the primary response-rate of aggregation and
the final response-maximal aggregation in response to 0.025 U/ml
thrombin. Inhibition of maximal aggregation was reached at
1 mM, the contribution of this receptor to platelet aggregation was
estimated about ,12% in our conditions. Similar results were
obtained in studies made on whole blood aggregation [16]. These
Figure 8. Effect of AR-C67085 concentrations on the cAMP levels in thrombin stimulated human platelets. Washed human platelets
were preincubated with a mixture of phosphodiesterase inhibitors for 5 min. Then, cells were incubated in the presence of various concentrations of
AR-C67085 (0.1, 1, 10 mM) or vehicle for 10 min and subsequently, were incubated in the presence of ATP (500 mM) or vehicle for 2 min. Finally, cells
were stimulated with 0.025 U/ml thrombin for 5 min in the presence of 1 mM CaCl2. The reaction was stopped by the addition of ice-cold TCA (10%
final concentration). The cAMP levels were determined as described in Experimental Procedures. Data are the means 6 s.e.m of 4 experiments with
different platelets preparations, performed in duplicate and assayed in triplicate. The increases in cAMP levels with respect to basal levels (D [cAMP],
pmol/109 platelets) are indicated. *P,0.5, **P,0.01 when compared to platelets not incubated with AR-C67085 in the absence of ATP and #P.0.05
in the presence of ATP, respectively.
doi:10.1371/journal.pone.0067117.g008
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results reveal that the inhibition of TIPA by ATP just cannot be
explained by competitive inhibition at ADP receptor levels. In
summary, we found that ATP increased cAMP levels by regulating
negatively the P2Y12 receptor activation mediated by ADP and
inhibiting platelet activation/aggregation induced by thrombin.
Extracellular nucleotides such as ATP, GTP and AMP are
involved in the activation of cyclooxygenase and 12-LO in washed
human platelets [24]. The arachidonic acid released by phospho-
lipase A2 is a substrate of 12-LO for the production of 12(S)-HETE
in platelets [61]. We have observed that ATP by itself did not
affect phospholipase A2 activity (not shown), furthermore throm-
bin increases the 12(S)-HETE levels [62]. This eicosatetraeonic
acid derivative modulates the platelet activity and pathological
thrombus in acute coronary syndromes [63]. Regarding to platelet
aggregation, it has been found that 12(S)-HETE enhances this
process mediated by agonists such as thrombin by decreasing
cAMP levels [63–65]. However, the inhibition of the 12-LO
activity by either NDGA or 15(S)-HETE, a more specific 12-LO
inhibitor, did not affect TIPA. Similar data have been obtained in
platelets from 12-LO knock-out mice [66]. ATP decreased 12(S)-
HETE levels in thrombin-stimulated human platelets, and its
inhibition on TIPA was reversed by blocking 12-LO. These results
suggest that a metabolite of the AA/12-LO pathway mediated the
inhibition of TIPA by ATP. Based on preliminary results showing
that ATP does not modify thrombin stimulated 12(S)-HpETE
formation (not shown), we hypothesize that a derivative of 12(S)-
HpETE different to 12(S)-HETE could be responsible for the
antiaggregant effect produced by ATP. In fact, there is evidence
supporting the role of these metabolites as inhibitors of platelet
aggregation induced by different agonists [67].
When both AC and 12-LO were simultaneously inactivated by
SQ-22536 and NDGA respectively, ATP-mediated TIPA inhibi-
Figure 9. Effect of NDGA on the ATP-mediated inhibition of platelet aggregation and on 12(S) Lipoxigenase activity stimulated by
thrombin. Washed human platelets were preincubated with (A) NDGA (1, 5, 10, 25, 50 y 75 mM) or vehicle for 5 min and then exposed to 250 mM
(m) and 500 mM (N) ATP or vehicle (&) for 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin (Y, time= 0). The aggregation was
measured for 10 min. Values represent the average of maximal aggregation (%, means6s.e.m) of 6 experiments with different platelet preparations.
Error bars are omitted when smaller than symbol. (B) cells were preincubated with 25 mM NDGA or vehicle and subsequently cells were incubated in
presence of 500 mM ATP or vehicle for 2 min. Values represent the extent of aggregation at 10 minutes (%, means6s.e.m) of 6 experiments with
different platelet preparations. (C) Cells were preincubated in the presence (+) or in the absence (-) of 25 mM NDGA for 5 min at 37uC and then with
500 mM ATP or vehicle for 2 min at 37uC. Finally, platelets were stimulated with 0,025 U/ml thrombin or vehicle (control) for 10 min at 37uC in the
presence of 1 mM CaCl2. The reaction was stopped with cold methanol. Levels of 12 (S)-HETE were determined as described in materials and
methods. The bars represent the average (mean 6 SEM) of 3 experiments determined in duplicate, with different platelet preparations. The results
express the concentration of 12 (S)-HETE ([12 (S)-HETE] pg/106 cells). (Inset) Cells were preincubated with 12 (S)-HPETE (0, 5, 1, 3 and 5 mM) or with 12
(S)-HETE (0, 5 and 10 mM) for 2 min at 37uC. Then, cells were stimulated with 0,025 U/ml thrombin in the presence of 1 mM CaCl2. Platelet
aggregation was measured for 10 min. Graph shows the values of the extent of aggregation at 10 min (%, mean 6 standard error) of 3 experiments
with different platelet preparations. Error bars are omitted when they are smaller than the symbol.
doi:10.1371/journal.pone.0067117.g009
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tion was almost completely abolished. This effect was additive not
synergistic, suggesting the presence of two different and indepen-
dent mechanisms whereby ATP exerted its inhibition. According
to with this, platelet incubated either with NDGA or 15(S)-HETE
did not lead to any significant change in cAMP levels (data not
shown), indicating that 12-LO inhibition did not interfere with the
effect of ATP on AC. Conversely the inhibition of AC with SQ-
22536 did not affect thrombin stimulated 12(S)-HETE formation
or ATP-mediated inhibition of this hydroxylipid (data not shown).
In conclusion, we have shown that the inhibition of either AC or
12-LO pathway reverses ATP-mediated inhibition of TIPA.
Furthermore, ATP exerts its inhibitory effect over TIPA at least
through two different and independent signalling routes: 1) by
regulating AC activity; the intracellular cAMP levels negatively
affects the intracellular signalling controlled by thrombin, and also
interferes with the ADP/P2Y12-receptor pathways led by throm-
bin. In addition, we postulate that the rapid effect of ATP on
TIPA inhibition could also be originated by a direct allosteric
interaction between the ATP and a P2 receptor different to P2Y12.
Although the molecular mechanism remains to be elucidated; 2)
through another unknown molecular mechanism that involves to
the 12-LO pathway. Future studies will focus on the P2 receptor
identification as well as the characterization of the molecular
Figure 10. Effect of NDGA on the ATP-mediated inhibition of platelet aggregation. Washed human platelets were preincubated with (A)
5 mM 15(S)-HETE or vehicle for 2 min. Then cells were incubated in the presence of 500 mM ATP or vehicle for 2 min. Finally, cells were stimulated
with 0.025 U/ml thrombin (Y, time= 0). The aggregation was measured for 10 min. Values represent the extent of aggregation at 10 minutes (%,
means6s.e.m) of 4 experiments with different platelet preparations. (B) cells were preincubated with 25 mM NDGA or vehicle for 5 min and with
200 mM SQ-22536 or vehicle for 2 min. Then, cells were incubated in the presence of 500 mM ATP or vehicle for 2 min. Finally, cells were stimulated
with 0.025 U/ml thrombin (Y, time= 0). The aggregation was measured for 10 min. Values represent the extent of aggregation at 10 minutes (%,
means6s.e.m) of 6 experiments with different platelet preparations.
doi:10.1371/journal.pone.0067117.g010
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events leading to the cooperation between cAMP and 12-LO
pathways to inhibit the platelet aggregation induced by thrombin.
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